Breaking News, Collaborations & Alliances

Catalent Partners with ViralClear on Potential Treatment for COVID-19

Catalent will be developing two oral dosage forms of ViralClear’s broad-spectrum anti-viral agent merimepodib.

By: Contract Pharma

Contract Pharma Staff

Catalent has signed an agreement with ViralClear Pharmaceuticals, a subsidiary of BioSig Technologies, to work on the development of a potential treatment for adults with advanced COVID-19. Catalent will be developing two oral dosage forms of ViralClear’s broad-spectrum anti-viral agent, merimepodib: a solution and a solid oral dosage form.   ViralClear is undertaking research to investigate the potential of Merimepodib to fight the SARS-CoV-2 virus, either as a standalone treatment, or in combi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters